EW
BMRN icon

Evoke Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Evoke Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,890
Closed -$276K – 81
2026
Q1 		$276K Buy
+4,890
New +$285K 0.01% 565
2025
Q4 		– Sell
-5,093
Closed -$276K – 689
2025
Q3 		$276K Buy
5,093
+86
+2% +$4.92K 0.01% 521
2025
Q2 		$275K Buy
+5,007
New +$295K 0.01% 473
2022
Q4 		– Sell
-150
Closed -$13K – 463
2022
Q3 		$13K Hold
150
– – ﹤0.01% 702
2022
Q2 		$12K Hold
150
– – ﹤0.01% 739
2022
Q1 		$12K Sell
150
-1,921
-93% -$161K ﹤0.01% 732
2021
Q4 		$183K Buy
2,071
+173
+9% +$14.3K 0.01% 379
2021
Q3 		$146K Buy
1,898
+104
+6% +$8.21K 0.01% 376
2021
Q2 		$150K Buy
1,794
+380
+27% +$30.1K 0.01% 391
2021
Q1 		$107K Buy
1,414
+1,264
+843% +$103K ﹤0.01% 367
2020
Q4 		$13K Hold
150
– – ﹤0.01% 539
2020
Q3 		$11K Hold
150
– – ﹤0.01% 540
2020
Q2 		$19K Sell
150
-120
-44% -$11.9K ﹤0.01% 470
2020
Q1 		$22.8K Buy
+270
New +$23.3K ﹤0.01% 423
2019
Q4 		– Sell
-170
Closed -$11.5K – 1273
2019
Q3 		$11.5K Buy
+170
New +$13.1K ﹤0.01% 792

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Evoke Wealth's BMRN Position: Q2 2026 in Review

Evoke Wealth sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 4,890 shares — an estimated $276K sold.

Evoke Wealth first reported a position in BMRN in Q3 2019 and held it in 15 quarters. The position peaked at $276K in Q1 2026. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Evoke Wealth reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Evoke Wealth sold 4,890 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $276K.
  • Evoke Wealth first reported a position in BioMarin Pharmaceuticals in Q3 2019 and held it in 15 quarters.
  • Evoke Wealth's BioMarin Pharmaceuticals position peaked at $276K in Q1 2026.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Evoke Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.